Coming-of-Age of Antibodies in Cancer Therapeutics

被引：83
作者：
Ayyar, B. Vijayalakshmi [1 ]
Arora, Sushrut [2 ]
O'Kennedy, Richard [3 ,4 ]
机构：
[1] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[3] Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland
[4] Dublin City Univ, Biomed Diagnost Inst, Dublin 9, Ireland
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 12期
基金：
爱尔兰科学基金会;
关键词：
IMMUNE CHECKPOINT INHIBITORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; SITE-SPECIFIC CONJUGATION; ANTI-TARGET CELL; BISPECIFIC ANTIBODIES; NEXT-GENERATION; MONOCLONAL-ANTIBODY; DRUG CONJUGATE; IMMUNOTHERAPY; RECEPTOR;
D O I：
10.1016/j.tips.2016.09.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Antibody-based therapies have garnered considerable success in recent years. This is due to the availability of strategies to successfully engineer antibodies into humanized forms, better understanding of the biological processes involved in cancer development, the availability of novel recombinant antibody formats, better antibody selection platforms, and improved antibody conjugation methodologies. Such achievements have led to an explosion in the generation of antibodies and antibody-associated constructs for the treatment of cancer and other diseases. In this review, we critically assess recent trends in the development and applications of bispecific antibodies (bsAbs), antibody drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) as cancer therapeutics. We also highlight recent US FDA approvals and clinical trials of antibody-based cancer therapies.
引用
收藏
页码：1009 / 1028
页数：20
相关论文
共 93 条
[1]  
Adams S., 2015, MOL CANC THAR, V14, pA89
[2]   T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct [J].
Aigner, M. ;
Feulner, J. ;
Schaffer, S. ;
Kischel, R. ;
Kufer, P. ;
Schneider, K. ;
Henn, A. ;
Rattel, B. ;
Friedrich, M. ;
Baeuerle, P. A. ;
Mackensen, A. ;
Krause, S. W. .
LEUKEMIA, 2013, 27 (05) :1107-1115
[3]   Antibody-drug conjugates: targeted drug delivery for cancer [J].
Alley, Stephen C. ;
Okeley, Nicole M. ;
Senter, Peter D. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537
[4]   Cancer immunotherapy: Past Progress and Future Directions [J].
Atkins, Michael B. ;
Sznol, Mario .
SEMINARS IN ONCOLOGY, 2015, 42 (04) :518-522
[5]   Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations [J].
Baksh, Kathryn ;
Weber, Jeffrey .
SEMINARS IN ONCOLOGY, 2015, 42 (03) :363-377
[6]   Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].
Bargou, Ralf ;
Leo, Eugen ;
Zugmaier, Gerhard ;
Klinger, Matthias ;
Goebeler, Mariele ;
Knop, Stefan ;
Noppeney, Richard ;
Viardot, Andreas ;
Hess, Georg ;
Schuler, Martin ;
Einsele, Hermann ;
Brandl, Christian ;
Wolf, Andreas ;
Kirchinger, Petra ;
Klappers, Petra ;
Schmidt, Margit ;
Riethmueller, Gert ;
Reinhardt, Carsten ;
Baeuerle, Patrick A. ;
Kufer, Peter .
SCIENCE, 2008, 321 (5891) :974-977
[7]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[8]   A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer [J].
Bender, Brendan ;
Leipold, Douglas D. ;
Xu, Keyang ;
Shen, Ben-Quan ;
Tibbitts, Jay ;
Friberg, Lena E. .
AAPS JOURNAL, 2014, 16 (05) :994-1008
[9]   MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors [J].
Brischwein, K ;
Schlereth, B ;
Guller, B ;
Steiger, C ;
Wolf, A ;
Lutterbuese, R ;
Offner, S ;
Locher, M ;
Urbig, T ;
Raum, T ;
Kleindienst, P ;
Wimberger, P ;
Kimmig, R ;
Fichtner, I ;
Kufer, P ;
Hofmeister, R ;
da Silva, AJ ;
Baeuerle, PA .
MOLECULAR IMMUNOLOGY, 2006, 43 (08) :1129-1143
[10]   A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications [J].
Byrne, Hannah ;
Conroy, Paul J. ;
Whisstock, James C. ;
O'Kennedy, Richard J. .
TRENDS IN BIOTECHNOLOGY, 2013, 31 (11) :621-632
12345678910